PacBio and Intus Bio have launched GutID, the first commercial human gut health test, showcasing their collaboration and innovation in microbiome research. GutID utilizes PacBio's HiFi sequencing ...
PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and discovery, today unveiled GutID, the first commercial human ...
Zacks.com on MSN6d
PacBio Stock May Gain Following the Collaborated Launch of GutIDWith PacBio's well-known sequencing accuracy and Intus Bio's patented strain-level resolution assay and AI-powered analysis, ...
“We are proud to partner with PacBio for their first human health-related commercial application,” said Paul Denslow, CEO of Intus Bio. “High accuracy, long-read sequencing is essential to ...
PacBio (PACB) and Intus Bio unveiled GutID, the first commercial human gut health test powered by Intus Bio’s groundbreaking Titan-1 platform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback